The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
Joachim Von Pawel
No relevant relationships to disclose
Sang-We Kim
No relevant relationships to disclose
David R. Spigel
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Christoph Zielinski
Honoraria - XXX
Maria Catherine Pietanza
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Honoraria - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Veerle de Pril
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Marc S. Ballas
Employment or Leadership Position - Bristol-Myers Squibb
Consultant or Advisory Role - ImClone Systems; Lilly
Stock Ownership - Abbott Laboratories (I); Bristol-Myers Squibb; Novartis (I)
Honoraria - ImClone Systems; Lilly
Research Funding - AstraZeneca; ImClone Systems; Lilly; Pfizer
Other Remuneration - ImClone Systems; Lilly
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; Roche